Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAPTOR-BC ribociclib effectiveness and resistance study in advanced breast cancer
2022-500764-35-00Phase 4Authorised
- Sponsor
- Institut für Frauengesundheit
- Start
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ribociclib in breast cancer, sponsored by Institut für Frauengesundheit. Primary endpoints: progression-free survival and overall survival. Planned start Oct 2022; status: authorised.
02
Drugs
ribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2022-500764-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500764-35-00.